Abstract
There is no effective medical treatment for primary sclerosing cholangitis (PSC), a chronic cholestatic liver disease that usually progresses to cirrhosis and liver failure. The aim of this study was to determine the safety and efficacy of etanercept, an inhibitor of tumor necrosis factor, in the treatment of PSC. Ten patients with clinically active PSC were studied. All had elevated serum alkaline phosphatase levels, cholangiograms that were diagnostic of PSC, and liver histology consistent with PSC. Five patients had elevated serum bilirubin levels, five had pruritus, eight had failed to respond to ursodiol and/or methotrexate, and six had rapidly recurring dominant bile duct strictures. Patients were to receive etanercept, 25 mg subcutaneously twice weekly, for 6 months if there were no side effects and for 1 year if there was evidence of efficacy after 6 months. Biochemical tests of liver function did not improve in any patient. Mean serum bilirubin levels increased significantly, from 2.0 to 3.6 mg/dl (P = 0.026). Two of the five patients with pruritus had resolution of pruritus during treatment with etanercept, recurrence when etanercept was stopped, and resolution when it was restarted, although there was little change in liver enzymes or bilirubin levels. There was no decrease in the rate of stricture formation and there were no side effects. Etanercept, at the dosage used, was well tolerated but not effective in the treatment of PSC. It may be helpful in treating pruritus due to cholestasis.
REFERENCES
Lee Y-M, Kaplan MM, ACG PGCot: Practice guidelines. Management of primary sclerosing cholangitis. Am J Gastro 97:528–534, 2002
Olsson R, Danielsson A, Jarnerot G, et al.: Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis. Gastroenterology 100:1319–1323, 1991
Fausa O, Schrumpf E, Elgjo K: Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 11:31–39, 1991
Braeger CP, Nicholls S, Murch SH, Stephens SM, TT: Tumor necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 339:89–91, 1992
Targan SR, Hanauer SB, van Deventer SJH, et al.:Ashort-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337:1029–1035, 1997
Present DH, Rutgeerts P, Targan S, van Deventer SJH, et al.: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398–1405, 1999
Meier PN, Hain B, Martin M: The spectrum of cytokines in bile and sera of patients with primary sclerosing cholangitis. Gastroenterology 116:A21, 1999
Weinblatt ME, Kremer JM, Bankhurst AD, et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259, 1999
Van Deventer SJ: Tumour necrosis factor and Crohn's diseases. Gut 40:443–448, 1997
Sandborn WJ: Biologic therapy of inflammatory bowel disease. Gastroenterology 1592-1608, 2002
Elliott MJ, Maini RN, Feldman M, et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105–1110, 1994
LaDuca JR, Gaspari AA: Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases. Dermatol Clin 19:617–635, 2001
Sandborn WJ, Hanauer SB, Katz S, et al.: Etanercept for active Crohn's disease: A randomised double-blind, placebo controlled trial. Gastroenterology 121:1088–1094, 2001
Moreland LW, Margolies G, Heck LW, et al.: Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 23:1849–1855, 1996
Scallon B, Cai A, Solowski N, et al.: Binding and functional comparisons of two types of tumor necorsis factor antagonists. J Pharmacol Exp Ther 301:418–426, 2002
Ludwig J, Barham S, LaRusso N, Elveback L, Wiesner R, McCall J: Morphologic features of chronic hepatitis associated with primary sclerosing cholangitis and chronic ulcerative colitis. Hepatology 1:632–640, 1981
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Epstein, M.P., Kaplan, M.M. A Pilot Study of Etanercept in the Treatment of Primary Sclerosing Cholangitis. Dig Dis Sci 49, 1–4 (2004). https://doi.org/10.1023/B:DDAS.0000011827.87103.2e
Issue Date:
DOI: https://doi.org/10.1023/B:DDAS.0000011827.87103.2e